← All trials
NCT06463587
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2024
- Primary completion
- May 19, 2028
- Completion date
- Jul 23, 2030
- First posted
- Jun 18, 2024
- Last posted
- Oct 1, 2024
- Enrollment
- 240
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Merck KGaALead sponsor
- Merck SeronoOfficial
- Merck SeronoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.